Kufril LS Syrup is a combination expectorant and bronchodilator formulation containing Ambroxol (15mg/5ml), Levosalbutamol (0.5mg/5ml), and Guaifenesin (50mg/5ml). Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing smooth muscles in the airways, resulting in relief from bronchospasm and improved airflow. Guaifenesin serves as an expectorant, promoting the thinning and loosening of mucus, which aids in productive cough and enhances mucus clearance. Kufril LS Syrup is indicated for the symptomatic treatment of respiratory conditions characterized by excessive or thickened mucus and bronchospasm, such as acute and chronic bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). The combined action of these active ingredients helps alleviate cough, reduce airway obstruction, and facilitate expectoration. It is recommended to use this medication under medical supervision, especially in patients with cardiovascular disorders, hypertension, or hypersensitivity to any component. Common side effects may include mild gastrointestinal discomfort, tremors, or headache. Dosage should be individualized based on patient age and clinical response.